Seagen Inc.
Q3 2022 Earnings Call
Oct 27, 2022, 4:30 p.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Operator
Good day and welcome to the Seagen third quarter 2022 financial results conference call. [Operator instructions] Please note, today's event is being recorded. I would now like to turn the conference over to Doug Maffei, vice president, investor relations. Please go ahead.
Doug Maffei -- Vice President, Investor Relations
Thank you, operator and good afternoon everyone. I am pleased to welcome you to Seagen's third quarter 2022 financial results conference call. This afternoon, we issued a press release with our results. The press release and supporting slides are available on our website in the Investors section, Events & Presentations page.
Speakers on today's call will be Roger Dansey, interim chief executive officer and chief medical officer; Todd Simpson, chief financial officer; and Chip Romp, executive vice president, commercial U.S. Following our prepared remarks, we will open the line for questions. We aim to keep this call to one hour and ask that you limit yourself to one question to give everyone an opportunity to participate in Q&A during our call today. Today's conference call will include forward-looking statements regarding future or anticipated events and results, including the company's 2022 financial outlook, anticipated product sales, revenues, costs and expenses; potential clinical and regulatory milestones, including data readouts and regulatory submissions, potential marketing approvals and commercial performance.
Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference including the difficulty in forecasting sales, revenues, costs and expenses, impacts related to the COVID-19 pandemic and the uncertainty associated with the pharmaceutical development and regulatory approval process. More information about the risks and uncertainties faced by Seagen is contained under the caption Risk Factors included in the company's quarterly report on Form 10-Q for the quarter ended June 30, 2022 filed with the Securities and Exchange Commission and the company's subsequent reports filed with the SEC. Now, I will turn the call over to Roger.
Roger Dansey -- Chief Medical Officer
Thank you, Doug. Good afternoon, everyone and welcome to our third quarter call. This was a quarter where we delivered strong financial results with total quarterly revenue of $510 million, representing growth of 20% compared to the same quarter last year and reflecting robust sales across our approved portfolio. We also made substantial progress on multiple fronts, including clinical, regulatory, research and corporate development.